Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 18, 2013 LXRX, VMW, SMI, CISG, ETRM, OSIR Are Seasonally Ripe To Go Down In the Next Five Weeks
January 18, 2013 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX), VMware Inc (NYSE:VMW), Semiconductor Manufacturing International Corp (NYSE:SMI), CNinsure Inc (NASDAQ:CISG), Enteromedics Inc (NASDAQ:ETRM), Osiris Therapeutics Inc (NASDAQ:OSIR) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php
The following stocks are expected to go Down:
Symbol Company Expected Return Odds By The Following Date LXRX Lexicon Pharmaceuticals Inc -3.58% 75.00% (9 of 12) Monday, January 21st 2013 VMW VMware Inc -3.03% 100.00% (5 of 5) Monday, January 21st 2013 SMI Semiconductor Manufacturing International Corp -2.51% 87.50% (7 of 8) Monday, January 21st 2013 CISG CNinsure Inc -3.15% 100.00% (5 of 5) Wednesday, February 6th 2013 ETRM Enteromedics Inc -7.21% 100.00% (5 of 5) Friday, March 1st 2013 OSIR Osiris Therapeutics Inc -16.83% 100.00% (6 of 6) Friday, March 1st 2013Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) - Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of drug programs in various stages of clinical development include LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, which is in Phase IIb clinical trials for the treatment of type 2 diabetes; LX1032, an inhibitor of tryptophan hydroxylase, is preparing for Phase III registrational trials to reduce peripheral serotonin production without affecting brain serotonin levels in patients with carcinoid syndrome, as well as initiated a Phase II proof-of-concept trial for patients with ulcerative colitis; and LX1033, a serotonin synthesis inhibitor that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company also develops LX2931, an inhibitor of sphingosine-1-phosphate lyase, which completed a Phase IIa clinical trials and conducting a dose-ranging study to explore higher doses as a treatment for rheumatoid arthritis and other autoimmune diseases; and LX7101, an orally-delivered small molecule compound that initiated a Phase I-II proof-of-concept study in glaucoma patients. It also has advanced small molecule compounds from various additional drug programs into various stages of preclinical development and research. The company has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas..
VMware Inc (NYSE:VMW) - VMware, Inc. provides virtualization and virtualization-based cloud infrastructure solutions in the United States and internationally. The company s products address planned and unplanned downtime management, system recoverability and reliability, backup and recovery, resource provisioning and management, capacity and performance management, and security issues. Its cloud infrastructure products and technologies include VMware vSphere, which is a data center platform that also enables live migration of actively running virtual machines across servers or storage locations without disruption or downtime; enables availability for all applications against hardware and operating system failures; and enables centralized point of control for cluster-level networking, as well as automatically manages the placement and balancing of a virtual machine across storage resources. The company also offers cloud application platform solutions that help organizations build, run, and manage enterprise applications in public, private, or hybrid clouds optimized for vSphere. In addition, it provides end-user computing solutions, which provide secure access to applications and data from various devices and location, as well as serves the corporate IT departments through managing and connecting end-user assets delivering them as a managed service. The company s end-user computing solutions also provide the ability to manage software as a service, Windows, Mobile, or enterprise applications, as well as enhance communication and collaboration between end users. Further, it provides a range of professional services, such as consulting, education, and technical account manager services, as well as customer support services. The company sells its products through distributors, resellers, system vendors, and systems integrators. VMware, Inc. was incorporated in 1998 and is headquartered in Palo Alto, California. VMware, Inc. operates as a subsidiary of EMC Corporation..
Semiconductor Manufacturing International Corp (NYSE:SMI) - Semiconductor Manufacturing International Corporation, an investment holding company, engages in computer-aided designing, manufacturing, packaging, testing, and trading integrated circuits and other semiconductor services. The company offers semiconductor fabrication services for devices, including logic technologies, such as standard logic, mixed-signal, radio frequency (RF), and high voltage circuits; memory technologies comprising static random access memory, flash, electrically erasable programmable read-only memory, and mask read-only memory; and specialty technologies, including liquid crystal on silicon (LCoS), complementary metal oxide silicon image sensor (CIS), micro electrical and mechanical system (MEMS), through silicon via (TSV), and integrated passive devices. Its semiconductors are used in various computing, communications, consumer, and industrial applications, such as computers, mobile telephones, digital televisions, digital cameras, DVD players, entertainment devices, other consumer electronics devices, and automotive and industrial applications. In addition, the company provides integrated solutions, such as design support services comprising libraries, intellectual property, and design center alliance accessing services, as well as design reference flows; mask-making services; and wafer probing, assembling, and testing services. It serves integrated device manufacturers, fables semiconductor companies, and system companies principally in the United States, Europe, the Asia Pacific, Japan, Taiwan, and China. Semiconductor Manufacturing International Corporation was founded in 2000 and is headquartered in Shanghai, the People s Republic of China..
CNinsure Inc (NASDAQ:CISG) - CNinsure Inc., an insurance intermediary company, provides insurance brokerage and agency, and insurance claims adjusting services in the People s Republic of China. The company distributes property and casualty, and life insurance products underwritten by various insurance companies. It sells automobile insurance, individual accident insurance, and homeowner insurance products primarily to individual customers; commercial property insurance, cargo insurance, hull insurance, liability insurance, and construction insurance products to institutional customers; and life insurance products, including individual whole life insurance, term life insurance, endowment life insurance, education annuity, and health insurance, as well as universal insurance and group life insurance primarily to individuals under 50 years of age. The company s insurance claims adjusting services include pre-underwriting survey, claims adjusting, disposal of residual value, loading and unloading supervision, and consulting services, as well as damage assessment, survey, authentication, and loss estimation to insurance companies and the insured. It also offers value-added services to its customers in conjunction with distributing automobile insurance products. In addition, the company distributes mortgage loans, re-mortgage loans, homeowner loans, and auto loans, as well as offers independent investment research and wealth management services to both institutions and individuals. As of April 8, 2011, its distribution and service network consisted of 39 insurance agencies, 3 insurance brokerages, 3 claims adjusting firms, and 1 online insurance service company, with 533 sales and service outlets, 45,914 registered sales agents, 124 in-house sales representatives, and 1,367 in-house claims adjustors. The company was founded in 1998 and is headquartered in Guangzhou, the People s Republic of China..
Enteromedics Inc (NASDAQ:ETRM) - EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company is developing Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, Norway, and Switzerland. It has collaborations with Mayo Clinic and Australian Institute of Weight Control for research and development of its products. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota..
Osiris Therapeutics Inc (NASDAQ:OSIR) - Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets. It operates in two segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment focuses on the development, manufacture, and distribution of biologic products for wound healing and use in surgical procedures by harnessing the ability of cells and novel constructs to promote the body's natural healing. This segment s marketed products comprise Grafix and Ovation for tissue repair. The company s lead biologic drug candidate is Prochymal, which is in Phase 2 and Phase 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidate also includes Chondrogen, a preparation of adult mesenchymal stem cells that is in Phase 2 clinical trials for osteoarthritis in the knee and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
- WOPRAI
- support@woprai.com